http://www.elsevier.nl/gej-ng/10/42/35/40/41/27/abstract.html

 

Full text PDF files should be viewed and printed using Adobe® Acrobat® Reader version 3.01 or higher (Download here). Further details about PDF and Adobe® Acrobat® Reader can be found on our "PDF FAQ" page.

Note: A new access control system has recently been introduced. You may need to register (once) for access, even if this was not necessary before. Thank you for your patience.



Vaccine, Vol. 19 (25-26) (2001) pp. 3331 - 3346
© 2001 Elsevier Science Ltd. All rights reserved.
PII: S0264-410X(01)00028-7

Review

Neonatal and early life vaccinology

Claire-Anne Siegrist * claire-anne.siegrist@medecine.unige.ch

WHO Collaborating Centre for Neonatal Vaccinology, Departments of Pediatrics and Pathology, University of Geneva, 1 Michel-Servet, 1211 Geneva 4, Switzerland

Received 20 September 2000; received in revised form 27 December 2000; accepted 8 January 2001

Abstract

Preclinical and human vaccine studies indicate that, although neonatal immunisation does not generally lead to rapid and strong antibody responses, it may result in an efficient immunological priming, which can serve as an excellent basis for future responses. The apparent impairment of CD4 and CD8 T-cell function in early life seems to result from suboptimal antigen-presenting cells-T cell interactions, which can be overcome by use of specific adjuvants or delivery systems. Although persistence of maternal antibodies may limit infant antibody responses, induction of T-cell responses largely remain unaffected by these passively transferred antibodies. Thus, neonatal priming and early boosting with vaccine formulations optimised for sufficient early life immunogenicity and maximal safety profiles, could allow better control of the huge infectious disease burden in early life.

Keywords: Neonates; Infants; Vaccine responses; Maternal antibodies

*Tel.: +41-22-7025778; fax: +41-22-7025801

[Full text] (PDF 272.9 Kb)

© Copyright 2001, Elsevier Science, All rights reserved.

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.